Journalartikel

Jahr der Veröffentlichung: 2019

Seiten: 508-517

Zeitschrift: Zeitschrift für Gastroenterologie

Bandnummer: 57

Heftnummer: 4

ISSN: 0044-2771

eISSN: 1439-7803

DOI Link: https://doi.org/10.1055/a-0784-8877

Verlag: Georg Thieme Verlag

Abstract: 

Nonalcoholic fatty liver disease (NAFLD) includes nonalcoholic fatty liver (NAFL), nonalcoholic steato hepatitis (NASH) and NASH cirrhosis. NAFLD is the leading cause of liver diseases in the Western world (Central Europe, United States). The NAFLD incidence increases because of increasing type 2 diabetes and obesity. This article reviews the scientific findings of epidemiology, diagnostic, and therapeutic management of NAFLD. Lifestyle modifications (low-caloric Mediterranean diet and exercise training) to reduce weight are a major factor in the treatment of NAFLD.

Pharmacological therapies may be useful in patients with NASH and fibrosis as well as nonresponders to lifestyle modifications. Currently, however, no pharmacological substances are approved for the indication NASH.

Harvard-Zitierstil: Roeb, E. and Geier, A. (2019) Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments, Zeitschrift für Gastroenterologie, 57(4), pp. 508-517. https://doi.org/10.1055/a-0784-8877

APA-Zitierstil: Roeb, E., & Geier, A. (2019). Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Zeitschrift für Gastroenterologie. 57(4), 508-517. https://doi.org/10.1055/a-0784-8877